Staging of myeloma. A preliminary study of staging factors and treatment in different stages.
Attempts were made to find prognostic factors in myeloma. In 16 deceased patients, urinary light chains, skeletal lesions, and the quantity of the monoclonal protein fraction in the serum were correlated to prognosis, in contrast to the electrophoretic mobility of the monoclonal fraction, the hemoglobin, the serum creatinine value, the serum calcium, or the intestinal calcium absorption. Skeletal calcium uptake was only numerically higher in mild myeloma than in advanced myeloma. Since these findings partially agreed with the staging procedure previously proposed by Salmon, a modification of this procedure was used to stage 50 myeloma patients. Survival was statistically significantly shorter in stage III than in stage I. A differentiated treatement with melphalan-prednisone in stage I, cytoxan infusions in stage II, and vincristine-cytoxan-prednisone in stage III is proposed. A preliminary comparison of nine patients in stage II-III given intensive treatment with 23 given melphalan-prednisone suggests a numerically, but not as yet a statistically significant increase in survival in the intensively treated group, which seems to have an 80% 2-year survival.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000473:pathology; D002118:Calcium / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000652:urine; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy; D009194:Myeloma Proteins / Q000097:blood; D009367:Neoplasm Staging / Q000379:methods; D011379:Prognosis
D000970:Antineoplastic Agents; D007147:Immunoglobulin Light Chains; D009194:Myeloma Proteins; D002118:Calcium